Skip to main content

Table 5 Change in outcome measures from beginning to end of study

From: Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]

 

N-acetylcysteine (n = 25)

Placebo (n = 25)

Likert Score

0.7

0.8

FEV 1 (litres)

0.03

0.15

Sa0 2 (%)

1.2

1.8

  1. The average change in Likert score, FEV1, VC and SaO2 from entry into the study to end of study (discharge or Day 7) are shown.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us